Triple Negative Breast Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +26 more
2022-04-06
Apr 6, 2022
G
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
Recruiting
  • Breast Cancer
  • +2 more
  • Charleroi, Hainaut, Belgium
  • +1 more
2022-04-06
Apr 6, 2022
N
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumor
  • +26 more
  • Huntersville, North Carolina
    Carolina BioOncology Institute
2022-04-06
Apr 6, 2022
G
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Recruiting
  • Triple Negative Breast Cancer
  • Breast Cancer
  • Fullerton, California
  • +7 more
2022-04-05
Apr 5, 2022
I
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Recruiting
  • Metastatic Uveal Melanoma
  • +3 more
  • Questionnaires
  • +3 more
  • Paris, France
    Institut Curie
2022-04-06
Apr 6, 2022
P
A Study of PY314 in Subjects With Advanced Solid Tumors
Recruiting
  • Advanced Solid Tumor
  • +8 more
  • PY314
  • Combination Therapy: PY314 + Pembrolizumab
  • Scottsdale, Arizona
  • +12 more
2022-03-28
Mar 28, 2022
T
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
Suspended
  • Triple Negative Breast Cancer
  • Anthracycline-refractory TNBC
  • Houston, Texas
    Houston Methodist Cancer Center
2022-03-28
Mar 28, 2022
P
A Study of PRT2527 in Patients With Advanced Solid Tumors
Recruiting
  • Sarcomas
  • +4 more
  • Denver, Colorado
  • +5 more
2022-04-04
Apr 4, 2022
S
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +26 more
2022-04-01
Apr 1, 2022
N
A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Active, not recruiting
  • Melanoma
  • +6 more
  • Scottsdale, Arizona
  • +13 more
2022-03-31
Mar 31, 2022
W
Cardiac Outcomes With Near-Complete Estrogen Deprivation
Not yet recruiting
  • Breast Cancer
  • +2 more
  • Adenosine Stress Cardiac Magnetic Resonance Imaging
  • +4 more
  • Durham, North Carolina
  • +2 more
2022-03-25
Mar 25, 2022
A
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Active, not recruiting
  • Triple Negative Breast Cancer
  • Gilbert, Arizona
  • +28 more
2022-03-31
Mar 31, 2022
G
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Recruiting
  • Triple Negative Breast Cancer
  • Chandler, Arizona
  • +16 more
2022-03-30
Mar 30, 2022
S
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Recruiting
  • Urothelial Carcinoma
  • +4 more
  • San Diego, California
  • +4 more
2022-03-30
Mar 30, 2022
L
A Study to Investigate LYL797 in Adults With Solid Tumors
Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • New Haven, Connecticut
  • +6 more
2022-03-29
Mar 29, 2022
U
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Recruiting
  • Breast Cancer
  • +2 more
    • Monza, Italy
    • +2 more
    2022-03-29
    Mar 29, 2022
    M
    Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
    Recruiting
    • Triple Negative Breast Cancer
    • Amadora, Lisboa, Portugal
    • +16 more
    2022-03-28
    Mar 28, 2022
    E
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer - 2022
    Completed
    • Solid Tumors
    • +11 more
    • Boston, Massachusetts
    • +8 more
    2022-03-18
    Mar 18, 2022
    U
    Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
    Active, not recruiting
    • Triple Negative Breast Cancer
    • Washington, District of Columbia
    • +4 more
    2022-03-16
    Mar 16, 2022
    W
    De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
    Recruiting
    • Triple Negative Breast Cancer
    • Live Biobank
    • New York, New York
    • +1 more
    2022-03-26
    Mar 26, 2022
    S
    Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
    Recruiting
    • Triple Negative Breast Cancer
    • Deferoxamine Plus Chemotherapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    2022-03-28
    Mar 28, 2022
    I
    QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
    Active, not recruiting
    • Triple Negative Breast Cancer
    • Aldoxorubicin HCl
    • +17 more
    • El Segundo, California
      Chan Soon-Shiong Institute for Medicine
    2022-03-28
    Mar 28, 2022
    H
    Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
    Recruiting
    • Sarcoma, Synovial
    • +8 more
    • CYCLOPHOSPHAMIDE and FLUDARABIN
    • +3 more
    • Jerusalem, Israel
      Hadassah Medical Organization
    2022-03-15
    Mar 15, 2022
    C
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
    Recruiting
    • Non-Small Cell Lung Cancer
    • +12 more
    • Tucson, Arizona
    • +26 more
    2022-03-24
    Mar 24, 2022
    M
    A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
    Recruiting
    • Breast Cancer
    • Triple Negative Breast Cancer
    • Birmingham, Alabama
    • +1 more
    2022-03-22
    Mar 22, 2022